AU2021270095A1 - 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative - Google Patents

1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative Download PDF

Info

Publication number
AU2021270095A1
AU2021270095A1 AU2021270095A AU2021270095A AU2021270095A1 AU 2021270095 A1 AU2021270095 A1 AU 2021270095A1 AU 2021270095 A AU2021270095 A AU 2021270095A AU 2021270095 A AU2021270095 A AU 2021270095A AU 2021270095 A1 AU2021270095 A1 AU 2021270095A1
Authority
AU
Australia
Prior art keywords
group
fluoro
indazole
amino
tetrahydropyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021270095A
Other languages
English (en)
Inventor
Yasuhiro Aga
Toru Hasegawa
Ken-Ichi Komori
Takashi Matsushita
Ayumi Ogawa
Hayato Shimizu
Yasunori Tokunaga
Haruka YAMADA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Corp filed Critical Ube Corp
Publication of AU2021270095A1 publication Critical patent/AU2021270095A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021270095A 2020-05-14 2021-05-13 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative Pending AU2021270095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-085420 2020-05-14
JP2020085420 2020-05-14
PCT/JP2021/018252 WO2021230325A1 (ja) 2020-05-14 2021-05-13 １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体

Publications (1)

Publication Number Publication Date
AU2021270095A1 true AU2021270095A1 (en) 2022-12-22

Family

ID=78524455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021270095A Pending AU2021270095A1 (en) 2020-05-14 2021-05-13 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative

Country Status (10)

Country Link
US (1) US20230192661A1 (https=)
EP (1) EP4151632A4 (https=)
JP (1) JP7661969B2 (https=)
KR (1) KR20230011967A (https=)
CN (1) CN115551846B (https=)
AU (1) AU2021270095A1 (https=)
BR (1) BR112022023058A2 (https=)
CA (1) CA3182964A1 (https=)
MX (1) MX2022014200A (https=)
WO (1) WO2021230325A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
EP4733297A1 (en) * 2023-06-22 2026-04-29 Antibody Therapeutics, Inc. Integrin-inhibiting small molecule compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123164A (en) 1995-08-30 2001-03-19 Searle & Co Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
ZA994406B (en) 1998-03-04 2000-02-11 Searle & Co Meta-azacyclic amino benzoic acid and derivatives thereof.
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
KR20010042614A (ko) * 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
JP2006514050A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体
WO2014015054A1 (en) * 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Also Published As

Publication number Publication date
CN115551846B (zh) 2024-03-08
JP7661969B2 (ja) 2025-04-15
EP4151632A4 (en) 2024-04-24
CA3182964A1 (en) 2021-11-18
JPWO2021230325A1 (https=) 2021-11-18
EP4151632A1 (en) 2023-03-22
WO2021230325A1 (ja) 2021-11-18
MX2022014200A (es) 2022-12-07
US20230192661A1 (en) 2023-06-22
KR20230011967A (ko) 2023-01-25
BR112022023058A2 (pt) 2022-12-20
CN115551846A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP7767492B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP7602573B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
US20250223288A1 (en) Amino acid compounds and methods of use
US9278968B2 (en) Imidazopyridine compounds
TWI383981B (zh) 苯并呋喃基衍生物
JP6242390B2 (ja) Ｃｓｆ−１ｒキナーゼ阻害剤としての２−アミノピラジン誘導体
JP2013545740A (ja) バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
WO2007055418A1 (ja) アザ置換スピロ誘導体
BRPI1011043B1 (pt) fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica
CA2681861A1 (en) Ornithine derivative
AU2021270095A1 (en) 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative
US20250049806A1 (en) Pharmaceutical composition for providing treatment for or preventing alport syndrome
WO2026021475A1 (zh) 一种三并环类化合物及其制备方法和用途
JP2008545756A (ja) 癌化学療法剤として有用な１−メチル−１ｈ−ピラゾール−４−カルボキサミド類
WO2010023512A1 (en) Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
RU2845863C1 (ru) Производное 1,4,5,6-тетрагидропиримидин-2-амина
US20100184777A1 (en) Substituted Pyrazinone Amides
JP5647379B2 (ja) キノリニルグルカゴン受容体モジュレーター
US20230286948A1 (en) Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
CA3136745C (en) Dosage forms and regimens for amino acid compounds
AU2024282595A1 (en) Novel benzamide derivative compound and pharmaceutical composition comprising same
CA3136745A1 (en) Dosage forms and regimens for amino acid compounds
JP2013542231A (ja) バニロイド受容体リガンドとしての置換された二環式芳香族カルボキサミド誘導体および尿素誘導体